Yugandhar Puvvala

We are cautiously optimistic about the future of this facility. But ultimately, USFDA has to take a decision in terms of the Warning Letter, so I cannot comment on what exactly they will do.

We have most of our generic Revlimid settlement quantities. We have sold it. We have nothing more to sell other than a minimal listing.

FY 2026 will be muted in terms of growth per se because obviously you said it right. Eugia-3 is yet to be cleared, and there's no superstar product which is going to come in FY 2026.

I expect this quarter onwards, we should go back to the previous levels, and I don't expect any further decline happening from here on.

The worst is over with respect to Unit 3 is concerned. We expect the production level should come back to normalcy by Q4.

We have taken whatever sales hit what we wanted to taken in Q4 of last year, okay? Now, Q1 onwards, it should be normal.

We treat Revlimid as one of opportunity, and so we will just keep that... we will launch it from October 1, that's the settlement date.